Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CBWTFNASDAQ:MXCTNASDAQ:NRCNASDAQ:OABI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBWTFCannabis Wheaton Income$0.06$0.06$0.02▼$0.07$79.09M0.97665,651 shs226,091 shsMXCTMaxCyte$2.21+1.8%$2.40$2.01▼$5.20$230.92M1.28610,591 shs626,480 shsNRCNational Research$17.24+1.4%$13.65$9.76▼$27.07$387.35M0.3894,687 shs70,079 shsOABIOmniAb$1.71+6.2%$1.59$1.22▼$4.96$196.64M-0.03663,292 shs492,704 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBWTFCannabis Wheaton Income0.00%+3.09%-3.23%+5.26%+201.51%MXCTMaxCyte+1.84%+2.79%+0.91%-20.50%-47.26%NRCNational Research+1.41%+2.80%+26.86%+23.67%-30.68%OABIOmniAb+6.21%+0.59%+23.91%-29.63%-57.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBWTFCannabis Wheaton Income1.4887 of 5 stars0.05.00.00.02.80.01.3MXCTMaxCyte3.1661 of 5 stars3.55.00.00.00.01.70.6NRCNational Research1.3742 of 5 stars0.02.01.70.01.22.51.3OABIOmniAb3.0345 of 5 stars3.51.00.00.02.73.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBWTFCannabis Wheaton Income 0.00N/AN/AN/AMXCTMaxCyte 3.00Buy$7.50239.37% UpsideNRCNational Research 0.00N/AN/AN/AOABIOmniAb 3.00Buy$7.00309.36% UpsideCurrent Analyst Ratings BreakdownLatest CBWTF, NRC, MXCT, and OABI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025OABIOmniAbBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/27/2025OABIOmniAbRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$7.00 ➝ $4.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBWTFCannabis Wheaton Income$89.29M0.89N/AN/A$0.06 per share1.00MXCTMaxCyte$37.68M6.24N/AN/A$1.95 per share1.13NRCNational Research$143.06M2.75$1.35 per share12.74$1.36 per share12.68OABIOmniAb$26.39M7.91N/AN/A$2.37 per share0.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBWTFCannabis Wheaton Income-$11.93M$0.016.01∞N/A16.56%18.53%8.13%N/AMXCTMaxCyte-$41.06M-$0.40N/AN/AN/A-110.92%-19.90%-17.24%8/5/2025 (Estimated)NRCNational Research$24.78M$1.0316.74∞N/A17.14%71.33%18.67%7/28/2025 (Estimated)OABIOmniAb-$62.03M-$0.58N/AN/AN/A-229.11%-21.37%-18.84%8/6/2025 (Estimated)Latest CBWTF, NRC, MXCT, and OABI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CBWTFCannabis Wheaton IncomeN/A$0.01N/A$0.01N/AN/A5/8/2025Q1 2025OABIOmniAb-$0.17-$0.17N/A-$0.17$4.49 million$4.15 million5/7/2025Q1 2025MXCTMaxCyte-$0.10-$0.10N/A-$0.10$9.05 million$10.39 million4/28/2025Q1 2025NRCNational ResearchN/A$0.25N/A$0.25N/A$33.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBWTFCannabis Wheaton IncomeN/AN/AN/AN/AN/AMXCTMaxCyteN/AN/AN/AN/AN/ANRCNational Research$0.482.78%N/A46.60%N/AOABIOmniAbN/AN/AN/AN/AN/ALatest CBWTF, NRC, MXCT, and OABI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/25/2025NRCNational Researchquarterly$0.124.1%6/27/20256/27/20257/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBWTFCannabis Wheaton Income0.020.680.34MXCTMaxCyteN/A12.2311.58NRCNational Research1.980.540.54OABIOmniAbN/A4.704.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBWTFCannabis Wheaton IncomeN/AMXCTMaxCyte68.81%NRCNational Research47.26%OABIOmniAb72.08%Insider OwnershipCompanyInsider OwnershipCBWTFCannabis Wheaton Income4.60%MXCTMaxCyte3.30%NRCNational Research2.00%OABIOmniAb8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBWTFCannabis Wheaton Income3691.32 billion1.26 billionNot OptionableMXCTMaxCyte80106.42 million102.90 millionOptionableNRCNational Research49022.78 million22.33 millionOptionableOABIOmniAb7122.14 million111.63 millionOptionableCBWTF, NRC, MXCT, and OABI HeadlinesRecent News About These CompaniesOmniAb, Inc. (NASDAQ:OABI) Shares Sold by Chicago Capital LLCJune 17, 2025 | marketbeat.comOmniAb, Inc. (NASDAQ:OABI) Short Interest Down 15.8% in MayJune 3, 2025 | marketbeat.comChairman of OmniAb Picks Up 3.0% More StockMay 19, 2025 | uk.finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Director Steven Love Purchases 25,000 SharesMay 15, 2025 | insidertrades.comInsider Buying: OmniAb, Inc. (NASDAQ:OABI) Director Buys 65,000 Shares of StockMay 14, 2025 | insidertrades.comOmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston SummitMay 13, 2025 | businesswire.comIs OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030?May 10, 2025 | insidermonkey.comOmniAb, Inc. (NASDAQ:OABI) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comOmniAb, Inc. (OABI) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comOmniAb Introduces the xPloration® Partner Access ProgramMay 9, 2025 | tmcnet.comOmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue EstimatesMay 8, 2025 | zacks.comOmniAb Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | businesswire.comVERAXA Biotech AG and OmniAb, Inc. Announce Co-Discovery Alliance for Novel Bispecific Antibody Drug Conjugate Program Targeting Solid TumorsMay 5, 2025 | quiverquant.comVERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate ProgramMay 5, 2025 | globenewswire.comCompanies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In GrowthApril 25, 2025 | finance.yahoo.comOmniAb Announces Two New Appointments to its Board of DirectorsApril 21, 2025 | finance.yahoo.comOmniAb Appoints New Directors to BoardApril 21, 2025 | tipranks.comLeerink Partners Sticks to Their Buy Rating for OmniAb (OABI)April 20, 2025 | markets.businessinsider.comKurt A. Gustafson Sells 11,963 Shares of OmniAb, Inc. (NASDAQ:OABI) StockApril 2, 2025 | insidertrades.comAnalyst Forecasts Just Became More Bearish On OmniAb, Inc. (NASDAQ:OABI)March 29, 2025 | uk.finance.yahoo.comOmniAb price target lowered to $4 from $7 at RBC CapitalMarch 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCBWTF, NRC, MXCT, and OABI Company DescriptionsCannabis Wheaton Income OTCMKTS:CBWTF$0.06 0.00 (0.00%) As of 06/24/2025 03:59 PM EasternAuxly Cannabis Group Inc. operates as a consumer packaged goods company in the cannabis products market in Canada. It focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. The company offers cannabis products under various forms, including vape catridges, infused pre-rolls, pre-rolled, vape pens, milled and dried flower, concentrates, chocolates, soft chews, oil drops, capsules, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names. It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. The company was incorporated in 1987 and is headquartered in Toronto, Canada.MaxCyte NASDAQ:MXCT$2.21 +0.04 (+1.84%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$2.17 -0.04 (-1.99%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.National Research NASDAQ:NRC$17.24 +0.24 (+1.41%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$17.24 0.00 (-0.03%) As of 06/24/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.OmniAb NASDAQ:OABI$1.71 +0.10 (+6.21%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$1.70 0.00 (-0.29%) As of 06/24/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
